# The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment

> **NCT04358224** · PHASE4 · COMPLETED · sponsor: **Jonathan A. Bernstein, MD** · enrollment: 12 (actual)

## Conditions studied

- Atopic Dermatitis
- Eczema

## Interventions

- **BIOLOGICAL:** Dupilumab Prefilled Syringe

## Key facts

- **NCT ID:** NCT04358224
- **Lead sponsor:** Jonathan A. Bernstein, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-01
- **Primary completion:** 2022-11-18
- **Final completion:** 2022-11-18
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04358224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04358224, "The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04358224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*